{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:40:58Z","timestamp":1789656058203,"version":"4.0.1"},"reference-count":56,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Frontline Gastroenterol"],"accepted":{"date-parts":[[2018,12,9]]},"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:p>Primary biliary cholangitis (PBC) is an autoimmune liver disease associated with altered lipoprotein metabolism, mainly cholesterol. Hypercholesterolaemia, a major modifiable risk factor for cardiovascular disease in the general population, occurs in 75%\u201395% of individuals with PBC. The impact of hypercholesterolaemia on cardiovascular risk in PBC, however, is controversial. Previous data have shown that hypercholesterolaemia in PBC is not always associated with an increase in cardiovascular events. However, patients with PBC with cardiovascular risk factors may still warrant cholesterol-lowering therapy. Treatment of hypercholesterolaemia in PBC poses unique challenges among primary care providers due to concerns of hepatotoxicity associated with cholesterol-lowering medications. This review summarises the current understanding of the pathophysiology of hypercholesterolaemia in PBC and its pertinent cardiovascular risk. We will also discuss indications for treatment and the efficacy and safety of available agents for hypercholesterolaemia in PBC.<\/jats:p>","DOI":"10.1136\/flgastro-2018-101124","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T17:19:21Z","timestamp":1547054361000},"page":"401-408","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":40,"title":["Hyperlipidaemia in primary biliary cholangitis: treatment, safety and efficacy"],"prefix":"10.1136","volume":"10","author":[{"given":"Martin I","family":"Wah-Suarez","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University Hospital \u2019Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez', Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0322-7705","authenticated-orcid":false,"given":"Christopher J","family":"Danford","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilas R","family":"Patwardhan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z Gordon","family":"Jiang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Bonder","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,1,9]]},"reference":[{"key":"2025090708335194000_10.4.401.1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840150518"},{"key":"2025090708335194000_10.4.401.2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12191"},{"key":"2025090708335194000_10.4.401.3","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.2.265"},{"key":"2025090708335194000_10.4.401.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901143400207"},{"key":"2025090708335194000_10.4.401.5","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v3.i4.93"},{"key":"2025090708335194000_10.4.401.6","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.079814"},{"key":"2025090708335194000_10.4.401.7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14218\/JCTH.2017.00064","article-title":"Risk of cardiovascular events in patients with primary biliary cholangitis - systematic review","volume":"6","author":"Suraweera","year":"2018","journal-title":"J Clin Transl Hepatol"},{"key":"2025090708335194000_10.4.401.8","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M400229-JLR200"},{"key":"2025090708335194000_10.4.401.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.01888.x"},{"key":"2025090708335194000_10.4.401.10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26018"},{"key":"2025090708335194000_10.4.401.11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27157"},{"key":"2025090708335194000_10.4.401.12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"2025090708335194000_10.4.401.13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22906"},{"key":"2025090708335194000_10.4.401.14","doi-asserted-by":"crossref","first-page":"924","DOI":"10.4254\/wjh.v8.i22.924","article-title":"Cholesterol metabolism in cholestatic liver disease and liver transplantation: from molecular mechanisms to clinical implications","volume":"8","author":"Nemes","year":"2016","journal-title":"World J Hepatol"},{"key":"2025090708335194000_10.4.401.15","first-page":"89","article-title":"Metabolism of cholesterol and low- and high-density lipoproteins in primary biliary cirrhosis: cholesterol absorption and synthesis related to lipoprotein levels and their kinetics","volume":"21","author":"Gylling","year":"1995","journal-title":"Hepatology"},{"key":"2025090708335194000_10.4.401.16","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0016-5085(82)80212-6","article-title":"Cholestatic lipoproteins--their pathogenesis and significance","volume":"83","author":"Sabesin","year":"1982","journal-title":"Gastroenterology"},{"key":"2025090708335194000_10.4.401.17","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(85)90642-0"},{"key":"2025090708335194000_10.4.401.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2006.11.036"},{"key":"2025090708335194000_10.4.401.19","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(87)90091-8"},{"key":"2025090708335194000_10.4.401.20","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(94)90006-X"},{"key":"2025090708335194000_10.4.401.21","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00501.2009"},{"key":"2025090708335194000_10.4.401.22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033442","article-title":"Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden","volume":"7","author":"Z\u00f6ller","year":"2012","journal-title":"PLoS One"},{"key":"2025090708335194000_10.4.401.23","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/hepr.12452","article-title":"Coronary artery disease in primary biliary cirrhosis: A systematic review and meta-analysis of observational studies","volume":"45","author":"Ungprasert","year":"2015","journal-title":"Hepatol Res"},{"key":"2025090708335194000_10.4.401.24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MCG.0000000000000029","article-title":"Metabolic syndrome associated with primary biliary cirrhosis","volume":"49","author":"Floreani","year":"2015","journal-title":"J Clin Gastroenterol"},{"key":"2025090708335194000_10.4.401.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.04.052"},{"key":"2025090708335194000_10.4.401.26","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2012.196733"},{"key":"2025090708335194000_10.4.401.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2016.07.510"},{"key":"2025090708335194000_10.4.401.28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.110.959247"},{"key":"2025090708335194000_10.4.401.29","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437738.63853.7a"},{"key":"2025090708335194000_10.4.401.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2376"},{"key":"2025090708335194000_10.4.401.31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0022-2275(20)31668-0","article-title":"Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration","volume":"42","author":"Del Puppo","year":"2001","journal-title":"J Lipid Res"},{"key":"2025090708335194000_10.4.401.32","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1007\/s10620-009-0988-9","article-title":"Statins in primary biliary cirrhosis: are they safe?","volume":"55","author":"Abu Rajab","year":"2010","journal-title":"Dig Dis Sci"},{"key":"2025090708335194000_10.4.401.33","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.atherosclerosis.2009.08.052","article-title":"Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment","volume":"209","author":"Stojakovic","year":"2010","journal-title":"Atherosclerosis"},{"key":"2025090708335194000_10.4.401.34","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","article-title":"Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"15","author":"Kim","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025090708335194000_10.4.401.35","first-page":"Online","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: recommendation statement","volume":"95","author":"Force USPST","year":"2017","journal-title":"Am Fam Physician"},{"key":"2025090708335194000_10.4.401.36","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ajg.2015.20","article-title":"A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia","volume":"110","author":"Hosonuma","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2025090708335194000_10.4.401.37","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"key":"2025090708335194000_10.4.401.38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1874192401004010120","article-title":"Fenofibrate in primary biliary cirrhosis: a pilot study","volume":"4","author":"Liberopoulos","year":"2010","journal-title":"Open Cardiovasc Med J"},{"key":"2025090708335194000_10.4.401.39","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1007\/s10620-016-4250-y","article-title":"Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score","volume":"61","author":"Hegade","year":"2016","journal-title":"Dig Dis Sci"},{"key":"2025090708335194000_10.4.401.40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/apt.13465","article-title":"Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes","volume":"43","author":"Cheung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090708335194000_10.4.401.41","first-page":"350","article-title":"Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis","volume":"104","author":"Dohmen","year":"2013","journal-title":"Fukuoka Igaku Zasshi"},{"key":"2025090708335194000_10.4.401.42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001282"},{"key":"2025090708335194000_10.4.401.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60656-3"},{"key":"2025090708335194000_10.4.401.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.08.103"},{"key":"2025090708335194000_10.4.401.45","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-9-200911030-00144"},{"key":"2025090708335194000_10.4.401.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"2025090708335194000_10.4.401.47","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med"},{"key":"2025090708335194000_10.4.401.48","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/jcph.832","article-title":"Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects with hepatic impairment","volume":"57","author":"Gibbs","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2025090708335194000_10.4.401.49","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840170408"},{"key":"2025090708335194000_10.4.401.50","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0025-6196(12)61815-1","article-title":"Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis","volume":"69","author":"Balan","year":"1994","journal-title":"Mayo Clin Proc"},{"key":"2025090708335194000_10.4.401.51","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)70183-5"},{"key":"2025090708335194000_10.4.401.52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61933-4"},{"key":"2025090708335194000_10.4.401.53","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.12.005"},{"key":"2025090708335194000_10.4.401.54","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29569"},{"key":"2025090708335194000_10.4.401.55","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1007\/s10620-007-0003-2","article-title":"Atorvastatin does not improve liver biochemistries or Mayo Risk Score in primary biliary cirrhosis","volume":"53","author":"Stanca","year":"2008","journal-title":"Dig Dis Sci"},{"key":"2025090708335194000_10.4.401.56","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1751-2980.2012.00574.x","article-title":"Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy","volume":"13","author":"Han","year":"2012","journal-title":"J Dig Dis"}],"container-title":["Frontline Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/flgastro-2018-101124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:34:03Z","timestamp":1757259243000},"score":1,"resource":{"primary":{"URL":"https:\/\/fg.bmj.com\/lookup\/doi\/10.1136\/flgastro-2018-101124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,9]]},"references-count":56,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,9,6]]},"published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1136\/flgastro-2018-101124"],"URL":"https:\/\/doi.org\/10.1136\/flgastro-2018-101124","relation":{},"ISSN":["2041-4137","2041-4145"],"issn-type":[{"value":"2041-4137","type":"print"},{"value":"2041-4145","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,9]]}}}